Pfizer shares reached a new 52-week high of $29.09 during Tuesday’s trading session before closing at $28.75. The move left the pharmaceutical company up about 20% year to date, as it continues to recover from the effects of declining COVID-related revenue over the past two years.

Trading volume topped 8.3 million shares, above normal levels and a sign of elevated investor attention.

The stock’s advance followed Pfizer’s strong second-quarter 2026 results. The company reported adjusted earnings per share of $0.77, beating analyst estimates of $0.68 by nine cents. Revenue came in at $15.03 billion, ahead of the expected $14.42 billion. Sales rose 2.6% from the same period a year earlier. For investors tracking whether Pfizer can stabilize growth beyond its pandemic-era products, the quarter added another data point showing performance above Wall Street expectations.

In response to the quarterly performance, Pfizer raised its full-year 2026 earnings-per-share outlook to a range of $2.80 to $3.00. Wall Street analysts are currently forecasting full-year EPS of $2.98. Erste Group Bank also lifted its fiscal 2026 EPS estimate for Pfizer after the report.

A major legal development also helped lift attention on the stock. Pfizer reached a confidential settlement covering more than 6,000 federal lawsuits tied to Depo-Provera, the contraceptive. The lawsuits alleged a connection between the drug and intracranial meningioma. The company said it admitted no wrongdoing, and the financial terms were not disclosed. The settlement removes a significant source of legal uncertainty that investors had been watching closely.

Pfizer’s cancer business remains an area of focus for analysts. Padcev is currently the leading growth driver in the segment, and the company also has development programs such as PF-08634404 that could support future revenue. Expanded oncology label indications are being monitored as possible offsets to pressure elsewhere in the business as older products face generic competition, making the pipeline and product mix an important part of the broader turnaround story.

The company also paid a quarterly dividend of $0.43 per share on September 1 to shareholders of record as of July 24. That payment translates to an annualized dividend of $1.72 per share and a yield of about 6%.

Wall Street views remain mixed. Royal Bank of Canada upgraded Pfizer from underperform to sector perform in June. HSBC downgraded the stock from buy to hold in July and cut its price target from $32 to $28. Cantor Fitzgerald has a neutral rating with a $27 target, while Wolfe Research rates the shares underperform with a $26 target. Overall, the analyst consensus remains “Hold,” with a mean price target of $28.28, slightly below Pfizer’s current trading level.

Institutional ownership stands at 68.36% of outstanding shares. Several smaller investment funds opened new positions in the first and second quarters of 2026. Pfizer’s 50-day moving average is $25.62, and its 200-day moving average is $26.30, both below the current share price.

The post Pfizer (PFE) Stock Surges to 52-Week Peak Following Strong Q2 Results and Major Legal Settlement appeared first on Blockonomi.